US FDA Is No Longer ‘Getting Crap’ From Sponsors In IND Safety Reports, Temple Says
Executive Summary
FDA’s Robert Temple says he is gratified by the way companies have implemented the agency’s guidance on IND safety reporting. Merck, AbbVie and Janssen representatives discuss issues with unblinding data and the value of an aggregate analysis at DIA’s annual meeting.